Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.euf.2025.06.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Durable responses to immune checkpoint inhibitor-based regimens for metastatic clear cell renal cell carcinoma stratified by IMDC risk groups: A pooled analysis of four randomized phase 3 trials.
Kidney Cancer
February 2025
Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Background: An immune checkpoint inhibitor (ICI) backbone is a standard of care for frontline metastatic clear cell renal cell carcinoma, involving either ICI doublet or tyrosine kinase inhibitor (TKI) with ICI. These phase 3 trials used a sunitinib control arm. The optimal regimen is uncertain.
View Article and Find Full Text PDFEffect of Age on Robotic-Assisted Radical Prostatectomy Outcomes: A Multi-center Analysis.
Urology
August 2025
Department of Urology, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, NY. Electronic address:
Objective: To evaluate the association between age and risk of perioperative complications and whether age-related increases in complication risk are of clinical significance in the era of robotic-assisted radical prostatectomies.
Methods: We pooled prostatectomy outcomes during 2012-2022 from Cornell (n = 585), Georgetown (n = 319), and Memorial Sloan Kettering (n = 6419) to assess the primary outcome of any major complication (Clavien-Dindo grade ≥3) within 30 days of surgery. We used multivariable regression to determine the relationship between age and complications, adjusting for surgeon volume and oncologic risk (prostate specific antigen, surgery grade group, extracapsular extension, seminal vesical invasion, lymph node involvement, and surgical margin status).
Reply to Alireza Ghoreifi, Jaffar Hussain, Wei Phin Tan, et al's Letter to the Editor re: Alec Zhu, Mary O. Strasser, Timothy D. McClure, et al. Comparative Effectiveness of Partial Gland Cryoablation Versus Robotic Radical Prostatectomy for Cancer Control. Eur Urol Focus 2024;10:843-50.
Eur Urol Focus
January 2025
Department of Urology New York-Presbyterian/Weill Cornell Medicine New York NY USA. Electronic address:
Reply to Kaushik P. Kolanukuduru, Michael Gorin, Ash K. Tewari, and Mani Menon's Letter to the Editor re: Alec Zhu, Mary O. Strasser, Timothy D. McClure, et al. Comparative Effectiveness of Partial Gland Cryoablation Versus Robotic Radical Prostatectomy for Cancer Control. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2024.04.008.
Eur Urol Focus
January 2025
Department of Urology, New York-Presbyterian/Weill Cornell Medicine, New York, NY, USA.
Use of Decipher Prostate Biopsy Test in Patients with Favorable-risk Disease Undergoing Conservative Management or Radical Prostatectomy in the Surveillance, Epidemiology, and End Results Registry.
Eur Urol Oncol
December 2024
Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA. Electronic address:
Background And Objective: The extent of prostate cancer found on biopsy, as well as prostate cancer grade and genomic tests, can affect clinical decision-making. The impact of these factors on the initial management approach and subsequent patient outcomes for men with favorable-grade prostate cancer has not yet been determined on a population level. Our objective was to explore the association of Decipher 22-gene genomic classifier (GC) biopsy testing on the initial use of conservative management versus radical prostatectomy (RP) and to determine the independent effect of GC scores on RP pathologic outcomes.
View Article and Find Full Text PDF